Loading company
Scynexis Inc.
SCYX · Nasdaq · ·
Next earnings: November 4, 2026
$4.67+1.0%Sep 29 close
- 1M
- -13.4%
- 6M
- -26.1%
- 1Y
- -24.2%
- 5Y
- -89.8%
SCYX · Nasdaq · ·
Next earnings: November 4, 2026
$4.67+1.0%Sep 29 close
Scynexis Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $235K | $1.4M | -82.77% |
| Profit | $7.4M | -$6.9M | +207.44% |
| Profit per share | $0.63 | -$1.11 | +156.76% |
| Free Cash Flow | -$25.5M | -$16.6M | -53.99% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“SCYNEXIS had a year of significant progress in 2023, laying the foundation for future success by monetizing our first antifungal, BREXAFEMME ® , and progressing the development of SCY-247, our next generation compound,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Triterpenoid antifungals (also known as “fungerps”) are a novel class of structurally distinct glucan synthase inhibitors that combine the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. They have demonstrated broad-spectrum antifungal activity against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains. Ibrexafungerp is the first representative of this novel class of antifungal agents. Ibrexafungerp, formerly known as SCY-078, is currently approved in the U.S. for the treatment of vulvovaginal candidiasis and is in late-stage of development for invasive candidiasis and other indications. SCY-247 is a next generation fungerp in pre-clinical development for the treatment of life-threatening and often multi-drug resistant fungal diseases including Candida auris infections.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Scynexis Inc.’s Item 2.02 8-K filed March 28, 2024; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Scynexis Inc. has no earnings call transcript available.